Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

41. Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations

will wane over a few days. Nasal decongestant products should be avoided. In some places, herbal products that contain various constituents, such as Ma Huang (ephedra), have been used in treating COVID-19. These products should be avoided in patients with epilepsy as they may interact with ASM and could exacerbate seizures. Patients should always be asked about nonprescription medication and natural product use when taking a medication history. Possible Drugs for Treating COVID-19 Several different (...) Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations COVID-19 | Pharmacotherapy and Epilepsy | American Epilepsy Society Google Tag Manager | | | You are here » COVID-19 | Pharmacotherapy and Epilepsy COVID-19 | Pharmacotherapy and Epilepsy T his page was last updated April 17, 2020 Managing Patients with Epilepsy during COVID-19 Pharmacotherapy-related Recommendations Prepared by a Task Force of the AES Council on Clinical Activities: Timothy Welty, PharmD

2020 American Epilepsy Society

42. Seizures after posterior fossa surgery: Exploring the unknown, a systematic review- Full Text available with Trip Pro

Seizures after posterior fossa surgery: Exploring the unknown, a systematic review- Seizures after posterior fossa surgery: Exploring the unknown, a systematic review- | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its (...) validity or suitability for dissemination as established information or for guiding clinical practice. Research Seizures after posterior fossa surgery: Exploring the unknown, a systematic review- Ravish R keni, Surya Prakash Rao, Luis Rafael Moscote-Salazar, Harsh Deora, Quiñones-Ossa GA, Amit Agrawal Ravish R keni ORCiD: https://orcid.org/0000-0002-6278-9540 Surya Prakash Rao Luis Rafael Moscote-Salazar Harsh Deora Quiñones-Ossa GA Amit Agrawal Corresponding Author DOI: License: This work is licensed

2020 Research Square

43. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. (Abstract)

Antiepileptic drugs as prophylaxis for postcraniotomy seizures. This is an updated version of the Cochrane Review previously published in 2018. The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period. Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within the first (...) month of cranial surgery. The use of antiepileptic drugs (AEDs) administered pre- or postoperatively to prevent seizures following cranial surgery has been investigated in a number of randomised controlled trials (RCTs).To determine the efficacy and safety of AEDs when used prophylactically in people undergoing craniotomy and to examine which AEDs are most effective.For the latest update we searched the following databases on 29 September 2019: Cochrane Epilepsy Group Specialized Register, CENTRAL

2020 Cochrane

44. Effect of cinnamaldehyde on Cav-1 and Survivin expression in epilepsy: a protocol of systematic review and meta-analysis Full Text available with Trip Pro

Effect of cinnamaldehyde on Cav-1 and Survivin expression in epilepsy: a protocol of systematic review and meta-analysis Inplasy Protocol 174 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

45. Clonazepam add-on therapy for drug-resistant epilepsy. (Abstract)

for adults and children with drug-resistant focal onset or generalised onset epileptic seizures, when compared with placebo or another antiepileptic agent.For the latest update we searched the following databases on 4 June 2019: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid) 1946 to 3 June, 2019. The Cochrane Register of Studies (CRS Web) includes the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and randomised or quasi-randomised (...) Clonazepam add-on therapy for drug-resistant epilepsy. This is an updated version of the original Cochrane Review published in 2018, Issue 5. Epilepsy affects over 70 million people worldwide, and nearly a quarter of patients with seizures have drug-resistant epilepsy. People with drug-resistant epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.To assess the efficacy and tolerability of clonazepam when used as an add-on therapy

2020 Cochrane

46. A systematic review to assess seizure risk with chloroquine therapy in persons with epilepsy Full Text available with Trip Pro

A systematic review to assess seizure risk with chloroquine therapy in persons with epilepsy A systematic review to assess seizure risk with chloroquine therapy in persons with epilepsy | medRxiv Search for this keyword A systematic review to assess seizure risk with chloroquine therapy in persons with epilepsy Sandipan Pati doi: https://doi.org/10.1101/2020.04.09.20056358 Sandipan Pati 1 Department of Neurology, University of Alabama at Birmingham , AL 2 Epilepsy and Cognitive Neurophysiology (...) Laboratory, University of Alabama at Birmingham , AL For correspondence: ABSTRACT Background The goal of this systematic review is to assess the published literature for seizure risk with chloroquine therapy in persons with and without epilepsy. With the COVID-19 pandemic, there is a desperate need for therapy against the SARS CoV-2 virus. Chloroquine is one proposed medication that has received substantial public attention. However, drug labeling in the package insertion states that persons

2020 Cold Spring Harbor Laboratory

47. EEG for children with complex febrile seizures. (Abstract)

complex febrile seizures among children.To assess the use of EEG and its timing after complex febrile seizures in children younger than five years of age.For the latest update of this review, we searched the following databases on 12 March 2019: Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (Ovid, 1946 to 11 March 2019); and ClinicalTrials.gov. We applied no language (...) restrictions.All randomised controlled trials (RCTs) that examined the utility of an EEG and its timing after complex febrile seizures in children.The review authors selected and retrieved the articles and independently assessed which articles should be included. Any disagreements were resolved by discussion and by consultation with the Cochrane Epilepsy Group. We applied standard methodological procedures expected by Cochrane.Of 48 potentially eligible studies, no RCTs met the inclusion criteria.We found

2020 Cochrane

48. Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP). (Abstract)

Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP). This is an updated version of the original Cochrane Review, published in 2016, Issue 7. Sudden Unexpected Death in Epilepsy (SUDEP) is defined as sudden, unexpected, witnessed or unwitnessed, non-traumatic or non-drowning death of people with epilepsy, with or without evidence of a seizure, excluding documented status epilepticus and in whom postmortem examination does not reveal a structural or toxicological cause (...) for death. SUDEP has a reported incidence of 1 to 2 per 1000 patient-years and represents the most common epilepsy-related cause of death. The presence and frequency of generalised tonic-clonic seizures (GTCS), male sex, early age of seizure onset, duration of epilepsy, and polytherapy are all predictors of risk of SUDEP. The exact pathophysiology of SUDEP is currently unknown, although GTCS-induced cardiac, respiratory, and brainstem dysfunction appears likely. Appropriately chosen antiepileptic drug

2020 Cochrane

49. COVID-19 in Patients with Seizures and Epilepsy: Interpretation of Relevant Knowledge of Presenting Signs and Symptoms Full Text available with Trip Pro

that exacerbation of seizures, especially from systemic effects of severe COVID-19 infections, will be a major concern. Given this likelihood, all caregivers of patients with epilepsy should take extra care to assist their patients in preventing potential COVID-19 infection. References Theodore WH, Porter RJ. Precipitation of epileptic seizures is influenced by the type of epileptic syndrome, patient variability, and environmental factors. Epilepsy: 100 Elementary Principles . London: W.B. Saunders Co. Ltd (...) stages of evolution. Realizing both the need for and limitation of current information, this summary provides a focused summary of pertinent clinical diagnostic information about neurological involvement of SARS-CoV-2 virus and COVID-19, especially in relationship to patients with seizures and epilepsy. General issues There are multiple factors which influence frequency of epileptic seizures, including systemic and environmental factors. 1 COVID-19 therefore may exacerbate epileptic seizures from

2020 American Epilepsy Society

50. Lamotrigine add-on therapy for drug-resistant focal epilepsy. (Abstract)

Lamotrigine add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2016. Epilepsy is a common neurological disorder, affecting 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is resistant to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the newer antiepileptic drugs. Lamotrigine, in combination with other antiepileptic drugs (...) (add-on), can reduce seizures, but with some adverse effects.To determine the effects of lamotrigine on (1) seizures, (2) adverse-effect profile, and (3) cognition and quality of life, compared to placebo, when used as an add-on treatment for people with drug-resistant focal epilepsy.For the latest update of the review, we searched the following databases on 9 March 2020: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to March 06, 2020). CRS Web includes randomized or quasi-randomized

2020 Cochrane

51. Associations between CYP3A4, CYP3A5 and SCN1A Polymorphisms and Carbamazepine Metabolism in Epilepsy: A Meta-analysis Full Text available with Trip Pro

is not associated with CBZ in epilepsy. These findings would improve the individualized therapy of epileptic patients in clinics. Competing Interest Statement The authors have declared no competing interest. Funding Statement This work was supported by Grants from the National Science Foundation of China (No. 81460560 and 81960664) and the Applied Basic Research Program of Yunnan Province of China (No.2017FB134). Author Declarations All relevant ethical guidelines have been followed; any necessary IRB (...) Associations between CYP3A4, CYP3A5 and SCN1A Polymorphisms and Carbamazepine Metabolism in Epilepsy: A Meta-analysis Associations between CYP3A4, CYP3A5 and SCN1A Polymorphisms and Carbamazepine Metabolism in Epilepsy: A Meta-analysis | medRxiv Search for this keyword Associations between CYP3A4, CYP3A5 and SCN1A Polymorphisms and Carbamazepine Metabolism in Epilepsy: A Meta-analysis Gui-Xin Zhao , Zheng Zhang , Wen-Ke Cai , Ming-Li Shen , Ping Wang , Gong-Hao He doi: https://doi.org/10.1101

2020 Cold Spring Harbor Laboratory

52. Oxcarbazepine add-on for drug-resistant focal epilepsy. (Abstract)

Oxcarbazepine add-on for drug-resistant focal epilepsy. Epilepsy is a common neurological disorder. In approximately 30% of epilepsy cases, seizures are uncontrolled by one antiepileptic drug (AED). These people require treatment with a combination of multiple AEDs and are described as having drug-resistant epilepsy. Oxcarbazepine is a keto-analogue of carbamazepine, an established AED, and can be used as an add-on treatment for drug-resistant epilepsy.To assess the efficacy and tolerability (...) , 99% CI 1.17 to 3.54; random-effects model; 6 studies; low-certainty evidence). Hyponatraemia occurred more frequently with oxcarbazepine treatment but not significantly so (RR 2.53, 99% CI 0.27 to 23.85; fixed-effect model; 6 studies; moderate-certainty evidence).Oxcarbazepine might be effective at reducing seizure frequency when used as an add-on for drug-resistant focal epilepsy. The efficacy outcomes - 50% or greater seizure reduction and seizure freedom - were derived from low-certainty

2020 Cochrane

53. F1000Prime recommendation of Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study. Full Text available with Trip Pro

Disorders Epilepsy Neurogenetics close Make sure you never miss a key paper Discover the articles of most relevance to your research Evaluate expert opinion on the most impactful research Understand the key points and context of the article close Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study. close Add comment User comments must be in English, comprehensible and relevant to the article under discussion. Faculty Opinions reserves the right to remove any (...) F1000Prime recommendation of Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study. Diagnostic yield of genetic tests in epilepsy: A meta... | Faculty Opinions On April 12th, 2020, F1000Prime became Faculty Opinions. See our to learn more. Welcome Guest 1 Recommendations info_outline Systematic Review / Meta-analysis New Finding close Classified As New Finding 1 Article Type Systematic Review / Meta-analysis More more_vert close Download article Export

2020 Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

54. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy

is a neurological condition characterised by episodes of abnormal electrical activity in the brain (recurrent seizures). The seizures can be focal or generalised. Current treatments Current treatments 2.2 The main treatment for epilepsy is antiepileptic drugs taken to prevent or reduce the occurrence of seizures. However, many people with epilepsy have drug-resistant epilepsy, which is refractory to drug treatment (estimates vary between 20% and 40% of people with epilepsy). They have frequent seizures (...) or neurological deficit, gait disturbance, visual field deficits, cognitive deficit or psychiatric disturbance, and amnestic disorder. 3.4 Patient commentary was sought but none was received. Committee comments Committee comments 3.5 The committee noted that, in adults, the procedure has primarily been used to treat temporal lobe epilepsy. In children it has primarily been used for hypothalamic hamartomas. 3.6 The committee was informed that the procedure is much less invasive than open surgery. MRI-guided

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

55. Vagal nerve stimulation for epilepsy and depression

Vagal nerve stimulation for epilepsy and depression Vagal nerve stimulation for epilepsy and depression | Washington State Health Care Authority Toggle search Toggle navigation Announcement Menu Apple Health Eligibility Manual Search Close menu Search form Search all of HCA Search Health care services and supports Search Billers, providers, & partners Search Employee & retiree benefits Search About HCA Search Vagal nerve stimulation for epilepsy and depression Vagal nerve stimulation (...) for epilepsy and depression Public comment period extended. Public comment on the vagal nerve stimulation draft report has been extended until close of business, March 30, 2020. Submit all comments to: Vagal nerve stimulation (VNS) for epilepsy and depression was first reviewed by the HTA in 2009. In 2013, a review of VNS medical literature was conducted to determine if newly available evidence published since 2008 was likely to change the original coverage determination. The technology was not selected

2020 Washington Health Care Authority

56. Epilepsy in older people. (Abstract)

Epilepsy in older people. Globally, as populations age there will be challenges and opportunities to deliver optimal health care to senior citizens. Epilepsy, a condition characterised by spontaneous recurrent seizures, is common in older adults (aged >65 years) and yet has received comparatively little attention in this age group. In this Review, we evaluate the underlying causes of epilepsy in older people, explore difficulties in establishing a diagnosis of epilepsy in this population (...) , discuss appropriate antiseizure medications, and evaluate potential surgical treatment options. We consider cognitive, psychological, and psychosocial comorbidities and the effect that epilepsy might have on an older person's broader social or care network in high-income versus middle-income and low-income countries. We emphasise the need for clinical trials to be more inclusive of older people with epilepsy to help inform therapeutic decision making and discuss whether measures to improve vascular

2020 Lancet

57. Models of community-based primary care for epilepsy in low- and middle-income countries

: The 24 reports identified comprise mostly care programs addressing active convulsive epilepsy. Phenobarbital has been used most frequently, although other conventional antiseizure medications (ASMs) have also been used, but none of the newer. Tolerability rates in these studies are high, but overall attrition is considerable. Other approaches include updating primary health care providers, reinforcing treatment adherence in clinics, and raising community awareness. In these programs, the coverage (...) of existing treatment gap in the community, epilepsy-related mortality, and comorbidity burden are only fleetingly addressed. None, however, explicitly describe sustainability plans. Conclusions: Cost-free provision, mostly of phenobarbital, has resulted in short-term seizure freedom in roughly half of the people with epilepsy in low- and middle-income countries. Future programs should include a range of ASMs. These should cover apart from seizure control and treatment adherence, primary health care

2020 EvidenceUpdates

58. Cenobamate (Xcopri) - partial onset seizures

Cenobamate (Xcopri) - partial onset seizures Drug Approval Package: XCOPRI XCOPRI " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: XCOPRI Company: SK Life Science, Inc. Application Number: 212839 Approval Date: 11/21/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

59. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome

–Gastaut syndrome treatment pathway is consistent with NICE's clinical guideline on epilepsies: diagnosis and management. The guideline recommends starting treatment with sodium valproate and, if seizures are not adequately controlled, adding lamotrigine. They added that they would consider trying other antiepileptic drugs if sodium valproate and lamotrigine together do not adequately control seizures. The committee was aware that the marketing authorisation for cannabidiol is for use as an adjuvant (...) Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome T echnology appraisal guidance Published: 18 December 2019 www.nice.org.uk/guidance/ta615 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

60. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome

having fewer nights with seizures, when there is a higher risk of sudden unexpected death in epilepsy. The patient and carer expert considered that reducing the duration of convulsive seizures and the frequency of other seizure types would improve the quality of life of people with Dravet syndrome. The committee concluded that there is an unmet need for treatments that reduce the number and duration of convulsive seizures, and that patients and their carers would value a new treatment option (...) convulsive seizures were less likely to die from epilepsy-related causes, and people taking cannabidiol were more likely to be free from convulsive seizures. The company used an Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 16 of 25observational study of people with epilepsy (Trinka et al. 2013) to model a 58% reduction in risk

2020 National Institute for Health and Clinical Excellence - Technology Appraisals